P2Y2 Receptor-mediated Lymphotoxin-α Secretion Regulates Intercellular Cell Adhesion Molecule-1 Expression in Vascular Smooth Muscle Cells
Overview
Affiliations
The proinflammatory cytokine lymphotoxin-α (LTA) is thought to contribute to the pathogenesis of atherosclerosis. However, the mechanisms that regulate its expression in vascular smooth muscle cells (VSMC) are poorly understood. The ability of exogenous nucleotides to stimulate LTA production was evaluated in VSMC by ELISA. The P2Y(2) nucleotide receptor (P2Y(2)R) agonist UTP stimulates a strong and sustained release of LTA from WT but not P2Y(2)R(-/-) SMC. Assessment of LTA gene transcription by LTA promoter-luciferase construct indicated that LTA levels are controlled at the level of transcription. We show using RNAi techniques that knockdown of the actin-binding protein filamin-A (FLNa) severely impaired nucleotide-induced Rho activation and consequent Rho-mediated LTA secretion. Reintroduction of FLNa in FLNa RNAi SMC rescued UTP-induced LTA expression. In addition, we found that UTP-stimulated LTA secretion is not sensitive to brefeldin A, which blocks the formation of vesicles involved in protein transport from the endoplasmic reticulum to the Golgi apparatus, suggesting that P2Y(2)R/filamin-mediated secretion of LTA is independent of the endoplasmic reticulum/Golgi secretory vesicle route. Furthermore, UTP selectively induces ICAM-1 expression in WT but not SMC expressing a truncated P2Y(2)R deficient in LTA secretion. These data suggest that P2Y(2)R recruits FLNa to provide a cytoskeletal scaffold necessary for Rho signaling pathway upstream of LTA release and subsequent stimulation of ICAM-1 expression on vascular smooth muscle cells.
Structural Remodeling of the Extracellular Matrix in Arteriogenesis: A Review.
Kulkarni R, Andraska E, McEnaney R Front Cardiovasc Med. 2021; 8:761007.
PMID: 34805316 PMC: 8602576. DOI: 10.3389/fcvm.2021.761007.
Filamin A Regulates Cardiovascular Remodeling.
Bandaru S, Ala C, Zhou A, Akyurek L Int J Mol Sci. 2021; 22(12).
PMID: 34207234 PMC: 8235345. DOI: 10.3390/ijms22126555.
P2 Receptors as Therapeutic Targets in the Salivary Gland: From Physiology to Dysfunction.
Khalafalla M, Woods L, Jasmer K, Munoz Forti K, Camden J, Jensen J Front Pharmacol. 2020; 11:222.
PMID: 32231563 PMC: 7082426. DOI: 10.3389/fphar.2020.00222.
P2Y R deletion ameliorates sialadenitis in IL-14α-transgenic mice.
Woods L, Camden J, Khalafalla M, Petris M, Erb L, Ambrus Jr J Oral Dis. 2018; 24(5):761-771.
PMID: 29297959 PMC: 6644053. DOI: 10.1111/odi.12823.
The P2Y nucleotide receptor is an inhibitor of vascular calcification.
Qian S, Regan J, Shelton M, Hoggatt A, Mohammad K, Herring P Atherosclerosis. 2016; 257:38-46.
PMID: 28038380 PMC: 5348113. DOI: 10.1016/j.atherosclerosis.2016.12.014.